Problem

Basecamp Research addresses biology’s “data wall”: AI models are increasingly limited by the availability and quality of biological sequence data from nature. Existing public datasets are highly redundant and biased—68% of sequence data in the SRA database comes from just five species—so models trained on them can miss the diversity, context, and evolutionary relationships needed to discover genuinely novel proteins. The practical consequence is weaker biological prediction and design, forcing researchers toward slower, resource-intensive experimental cycles; even protein-structure determination remains dependent on time-consuming laboratory methods.

The highest-value use case is therapeutic and biological-system design, where better models can reduce discovery time and expand the set of viable candidates. Basecamp’s recent demonstrations focus on programmable gene insertion for replacing faulty genes and on antimicrobial peptides for drug-resistant infections, while its commercial examples include designing detergent enzymes that work at cold temperatures. Its data-permission model also targets a less visible economic pain: avoiding the delays and commercialization risk associated with unclear provenance, permissions, and benefit-sharing.

Product / Service

Basecamp combines a proprietary biodiversity data supply chain with biological foundation models and partner-oriented design work. Through global, partnership-based sampling and sequencing, it builds BaseData—the company’s newer name for its biological training database—and related infrastructure such as BaseGraph. The company reported that BaseData contained nearly 10 billion genes from more than one million newly discovered species and could grow by more than two billion genes per month. Access-and-benefit-sharing agreements, permissions, and traceability are designed into the data so that sequences can be used for biotechnology R&D, model training, and product development without post hoc commercialization negotiations.

On top of this data, Basecamp develops models including BaseFold for large-protein structure prediction and the EDEN family for generative biological design. EDEN powers the company’s AI-Programmable Gene Insertion platform, designing insertion proteins from genomic target sites, and has also been used for antimicrobial-peptide and microbiome design. The delivery model is primarily B2B: Basecamp works with research, biopharma, and industrial partners to match and refine proteins for specific applications, while selected EDEN models have also been made available through Claude Science. The benefit is a route from evolutionary data to experimentally testable protein and therapeutic candidates without relying solely on conventional trial-and-error discovery.

Market

Basecamp competes in AI-enabled computational biology, biological foundation models, protein design, and AI-assisted drug discovery. Its differentiation is the combination of a large, actively collected biodiversity dataset with models intended to design biological systems, rather than relying only on existing public databases or narrow experiment-generated datasets. The clearest named adjacent benchmark is DeepMind’s AlphaFold2 in protein-structure prediction; the broader competitive set consists of other AI drug-discovery and protein-design companies, although the evidence gathered does not establish a definitive like-for-like competitor list.

The company shows substantial early commercial and ecosystem traction rather than looking purely pre-product: by October 2024 it reported more than 100 partnerships across 25 countries, with roughly 15 organizations using its AI to build new products, including Procter & Gamble and three large drugmakers. It also announced a multi-year collaboration with David Liu’s lab at the Broad Institute, had raised $85 million since its 2019 founding according to contemporaneous reporting, and expanded distribution through the 2026 Claude Science launch. Revenue and contract values are not disclosed in the available evidence, so commercial usage and partnerships are stronger indicators of traction than a confirmed revenue scale.